WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay Johns
Hopkins University, Becton Dickinson & Company, and Baxter Healthcare
Corp. $7 million in damages for its willful infringement of patents involving
stem cell selection technology.
The judge also ordered an injunction against CellPro's patent-infringing
stem cell selection system (Ceprate Stem Cell Concentration System and
Ceprate LC34 Laboratory Cell Separation System). This injunction will be
delayed in this country until an alternative system, licensed under the
patents, is approved by the FDA.
Johns Hopkins and its licensees requested the delay to ensure that transplant
patients have uninterrupted access to stem cell selection technology. Baxter's
Isolex 300 Magnetic Cell Separator System, already in widespread use in
clinical trials, is currently under FDA review.